CTRI/2021/03/032116
Not yet recruiting
未知
AN OPEN LABEL, SINGLE ARM CLINICAL STUDY ON THE EFFECTIVENESS OF VADAVANALA CHURNA IN HYPOTHYROIDISM
sri dharmasthala manjunatheshwara college of ayurveda and hospital0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: E038- Other specified hypothyroidism
- Sponsor
- sri dharmasthala manjunatheshwara college of ayurveda and hospital
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.THOSE WHO ARE NEWLY DETECTED OR ON ORAL THYROXINE THERAPHY
- •2\. SUBJECTS OF EITHER GENDER
- •3\. SUBJECTS AGED BETWEEN 18 \- 60 YEARS
Exclusion Criteria
- •1\.SUBJECTS WITH HISTORY OF THYROIDECTOMY, CONGENITAL HYPOTHYROIDISM, DRUG INDUCED, HYPOTHYROIDISM DUE TO INFILTRATIVE DISORDERS SACOIDOSIS, SYSTEMIC SCLEROSIS, HEMOCHROMATOSIS, PROGRESSIVE CASE OF MYXOEDEMA
- •2\.KNOWN CASE OF RENAL, CARDIAC AND HEPATIC IMPAIRMENT
- •3\.KNOWN CASE OF DIABETES MELLITUS AND MALIGNANT HYPERTENSION
- •4\.PREGNANT AND LACTATING WOME
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Effect of Marmani Vati Lepa in IV cannula site swellingHealth Condition 1: 3- AdministrationHealth Condition 2: Z00-Z99- Factors influencing health status and contact with health servicesCTRI/2022/03/040773Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
Recruiting
Phase 2
A Clinical Study on Vasa Khanda Kushmanda Avaleha (Ayurveda Medicine) in Acid Peptic Disease (Amlapitta)Health Condition 1: null- acid peptic disorder(amlapitta)CTRI/2017/10/010032Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital Hassan30
Active, not recruiting
Phase 1
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2016-002937-31-SEF. Hoffmann-La Roche Ltd1,225
Completed
Phase 3
An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosisNL-OMON50626Roche Nederland B.V.24
Active, not recruiting
Phase 1
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2016-002937-31-DEF. Hoffmann-La Roche Ltd1,225